Replies to post #104075 on Ayala Pharmaceuticals Inc (ADXS)

[hdwrsft]

But, still, even with low sample size, given the unique approach (remember, we cancelled NEO for HOT, NEO was the approach Amgen bought into, then sprinted toward the exits), I would've expected, after all this time and effort, at least 1 CR or PR with HOT.


Seems like hitting the ball out of the ballpark just ain't happening.


This was more like a bunt to make it to first base.